At 4 years, about 20% of patients with advanced melanoma who received tumor-infiltrating lymphocyte therapy were alive and responding to treatment.

Further studying the biology of minimal residual disease may uncover ovarian cancer vulnerabilities and inform more effective therapies.

More work is needed to expand access to novel CAR T-cell therapies and bispecific agents among community oncologists, according to Al-Ola A. Abdallah, MD.

Following the approval of dato-DXd in untreated EGFR-mutant NSCLC, Jacob Sands, MD, discussed next steps for improving outcomes for this disease.

The complete response letter for the agent is due to observations from an FDA general site inspection at Catalent Indiana, LLC.

Developers plan to initiate a phase 2b trial in patients with less severe prostate cancer variants to better assess INKmune’s antitumor effects.

Jacob Sands, MD, discussed considerations for EGFR-mutant non–small cell lung cancer following the approval of dato-DXd in this disease.

Nonrandomized phase 2 data support further assessment of aumolertinib among patients with NSCLC and brain metastases in a randomized clinical trial.

Leading experts gathered in Orlando, Florida, to discuss the current and future state of cellular therapy in oncology at the 2025 ICE-T Symposium.

The biomarker analysis in KEYNOTE-426 showed that pembrolizumab plus axitinib therapy is associated with positive outcomes with angiogenesis in RCC.

Barry Paul, MD, believes cilta-cel, anito-cel, and arlo-cel are some of the most promising CAR T-cell therapies in the multiple myeloma space.

The field is just beginning to open the door for cellular therapy in lung cancer and other solid tumors, according to Daniel R. Carrizosa, MD, MS, FACP.

An ongoing, open-label phase 1 study evaluating VT3989 in mesothelioma revealed positive early efficacy and encouraging safety with the agent.

Findings from the phase 3 TALAPRO-2 trial showed that the safety profile of talazoparib was consistent with its known profile in metastatic CRPC.

Manojkumar Bupathi, MD, MS, and Benjamin Garmezy, MD, focus on treatment options for patients with urothelial carcinoma.

The treatment combination elicited partial responses in 80% of patients with squamous NSCLC and 46% in nonsquamous NSCLC.

A recently published study showed that a multicancer early detection blood test was able to identify cancer 3 or more years before a diagnosis.

Oncologists explore the considerations of mirvetuximab soravtansine treatment in platinum-resistant ovarian cancer, highlighting its efficacy and the management of ocular AEs.

SAR446523 is currently being evaluated in a first-in-human, phase 1 trial in patients with pretreated relapsed/refractory multiple myeloma.

Data from the LITESPARK-005 Q-TWiST analysis show belzutifan’s improved quality-adjusted survival time and favorable toxicity profile vs everolimus in RCC.

Phase 2 CRDF-004 results revealed that the addition of onvansertib to chemotherapy/bevacizumab was well tolerated, with no unexpected toxicities observed.

Innovative oncolytic virus therapies transform advanced melanoma treatment, enhance patient outcomes, and overcome resistance to traditional immunotherapies.

Data from the phase 3 BRUIN CLL-314 trial show a progression-free survival trend favoring pirtobrutinib compared with ibrutinib in patients with CLL/SLL.

Priya Jayachandran, MD, FACP, spoke about her new position at El Camino Health as well as her career as a breast oncologist.

Results from the phase 3 VIKTORIA-1 trial showed gedatolisib plus fulvestrant with or without palbociclib improved progression-free survival.